A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Type of Cancer
Genito-Urinary

Sponsor
Seattle Genetics

Protocol Number
SGN22E-002

To Learn More Call
(201)-510-0950